3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Neoplasms, Plasma Cell
1
Multiple Myeloma
1
Interventions
Melphalan
16
Dexamethasone
15
Bortezomib
11
Peripheral Blood Stem Cell Transplantation
9
Lenalidomide
9
fludarabine phosphate
8
Calcium Dobesilate
7
pomalidomide
5
fludarabine
5
Busulfan
5
carfilzomib
4
Radiotherapy
4
Prednisone
4
Cyclophosphamide
4
liposomal doxorubicin
3
daratumumab
3
Tacrolimus
3
Mycophenolic Acid
3
Methotrexate
3
Filgrastim
3
Cyclosporine
3
Arsenic Trioxide
3
Alemtuzumab
3
samarium Sm-153 lexidronam
2
holmium-1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetrakis(methylenephosphonic acid)
2
Whole-Body Irradiation
2
Surveys and Questionnaires
2
Pneumococcal Vaccines
2
Granulocyte Colony-Stimulating Factor
2
Bendamustine Hydrochloride
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Neoplasms, Plasma Cell
×
Warfarin
×
Clear all
NCT00790842
2018-10-24
PrE1003
PrECOG, LLC.
Phase 1/2
Terminated
63 enrolled
14 charts